Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech

0 Ratings
0
Episode
215 of 215
Duration
30min
Language
English
Format
Category
Economy & Business

Alnylam Pharmaceuticals has pioneered RNA interference therapeutics, or RNAi. This groundbreaking technology has increased the company’s success rates of bringing medicines through the clinical pipeline—leading to the approval and launch of six new medicines in just six years. Their CEO Dr. Yvonne Greenstreet spoke with Jerry Lee, head of biopharma banking in the global healthcare group, about the applications of Alnylam’s Nobel Prize-winning RNAi technology, her vision for the future of biotech, and the importance of a patient-focused and teamwork-oriented culture. Dr. Greenstreet also discussed her career journey and leadership philosophy —as one of the only women of color leading a major pharmaceutical company.

This episode was recorded on April 23, 2025. Learn more about your ad choices. Visit megaphone.fm/adchoices


Listen and read

Step into an infinite world of stories

  • Read and listen as much as you want
  • Over 1 million titles
  • Exclusive titles + Storytel Originals
  • 14 days free trial, then €9.99/month
  • Easy to cancel anytime
Try for free
Details page - Device banner - 894x1036

Other podcasts you might like ...